Controlling the development of vascular calcification in chronic kidney disease is essential, because it is associated with increased cardiovascular pathology. However, the precise mechanism of vascular calcification has not been completely elucidated. In the literature, the involvement of passive calcium and phosphate deposition as well as an active process stimulating the transformation of vascular smooth muscle cells into an osteoblastic phenotype is suggested. New promising insights into the etiology could lead to better treatment strategies, as Mizobuchi et al. now report.
treatment has the potential risk of aggravating hyperphosphatemia and inducing severe hypercalcemia as overcompensation for the initial low calcium levels. These disturbances in calcium and phosphate homeostasis are postulated to play an important role in the pathogenesis of vascular calcification (VC). Indeed, VC is frequently observed in CKD and is associated with increased morbidity and mortality from cardiovascular events. Therefore, controlling the process of VC is an essential aspect of CKD treatment. To date, new factors stimulating VC are being recognized, which motivates researchers to further unravel the exact mechanisms involved.
Previously, it was postulated that VC in CKD was caused merely by a passive deposition of calcium × phosphate<1> (Ca × P) products in the vascular system, which were generated because of hyperphosphatemia and hypercalcemia. Indeed, many studies in both animals and humans have shown a strong positive correlation between hyperphosphatemia, hypercalcemia, and VC. 1, 2 Furthermore, in vitro studies exposing vascular smooth muscle cells (VSMCs) to high phosphate and calcium concentrations showed a dosedependent increase in mineralization. 3, 4 However, several recent studies described phenotypic changes of VSMCs in the vessel wall of uremic animals, indicating the involvement of a more complex mechanism. In fact, a number of proteins were present in elevated amounts in the calcified vessel and were likely to be involved in promoting differentiation of VSMCs into an osteoblastic phenotype. 1 This modification is driven by the upregulation of certain transcription factors, including core-binding factor 1α (cbfa1), also known as Runx2, and bone morphogenetic protein-2 (bmp-2), which are key regulators of VSMC differentiation by controlling the expression of a number of osteogenic proteins, such as osteocalcin, osteonectin, alkaline phosphatase, and collagen-1. This hypothesis was confirmed in studies that exposed VSMCs to high phosphate and calcium concentrations and showed upregulation of cbfa1 and increased alkaline phosphatase production. 3, 5 Furthermore, these osteoblastic markers are found to be elevated in the vasculature of both uremic rats and CKD patients. 1, 2 In addition, another predominant mechanism by which VC occurs is through the loss of inhibitors. Several protective factors produced by endothelial cells were recognized that are able to prevent soft tissue calcifications under normal conditions. Important protectors include matrix Gla-protein, osteopontin, fetuin, and osteoprotegerin, which inhibit different pathways involved in the pathogenesis of VC. Ultimately, a disproportion in the production of both VC-promoting and VC-inhibiting factors could shift the VSMCs toward an osteoblast-like phenotype.<2> The crucial question remains: what triggers this imbalance?
Contribution of high phosphate levels to VSMC differentiation is thought to be driven by the upregulation of a type III sodium-dependent cotransporter, called Pit-I, stimulation of<3> which can subsequently upregulate cbfa1 expression. 3, 5, 6 Additionally, proinflammatory cytokines have been postulated to reduce the ability of endothelial cells to produce certain inhibitory factors, subsequently accelerating the VC process. However, further research will be required in this area to provide detailed evidence for the hypothesized pathways involved in VC as mentioned above.
Interestingly, vitamin D receptor (VDR) 7 One explanation for this beneficial effect could be that 1,25(OH) 2 D 3 protects VSMCs from calcification by suppressing cbfa1 and bmp-2 synthesis. 8, 9 Consequently, vitamin D or VDR agonist supplementation remains extremely important, although the risk of highly elevated serum calcium and phosphate levels can clearly accelerate the VC process. Therefore, it is crucial to develop drugs that can sufficiently reduce SHPT but have less hypercalcemic and hyperphosphatemic activity.
This topic was successfully addressed by Mizobuchi et al. 10 (this issue), who investigated the effects of supplementing various VDR agonists, including doxercalciferol and paricalcitol, on VC. They showed that doxercalciferol was less hypercalcemic and hyperphosphatemic than 1,25(OH) 2 D 3 , but it still induced mineralization and increased the osteogenic markers cbfa1 and osteocalcin in the vasculature. Interestingly, they observed that in uremic rats paricalcitol did not exert hypercalcemic and hyperphosphatemic effects resulting in reduced Ca × P products and diminished mineralization of the vasculature. Besides, paricalcitol had no stimulatory effect on cbfa1 and osteocalcin expression. 10 Highly essential for CKD treatment is the fact that paricalcitol maintained the ability to efficiently reduce the SHPT. Although the exact mechanism of differential effects between doxercalciferol and paricalcitol is unknown, it can be concluded from this study that paricalcitol is favorable over doxercalciferol in CKD therapy. These results are further supported by a study in which dialysis patients were treated with either calcitriol or paricalcitol. The paricalcitol-treated group showed not only a significantly improved survival benefit, indicated by a 16% reduced mortality rate, 11 but also a reduced number of hospitalizations and reduced hospitalization time as well. 12 Likewise, Tentori et al. 13 reported a higher mortality for patients on 1,25(OH) 2 D 3 treatment as compared with paricalcitol and doxercalciferol, although the effect was small. In contrast to the findings described by Mizobuchi et al., 10 <4> the mortality rates were similar for paricalcitol versus doxercalciferol. 13 In conclusion, we can learn from these new studies that the control of plasma calcium and phosphate in CKD patients is important in prevention of VC. New information<5> about the precise regulators of VSMC differentiation into osteoblastic cells is rapidly increasing. Future studies should now focus on unraveling the VC pathways in detail and investigating the exact differences among the diverse vitamin D agonists in order to develop new drugs that can specifically treat SHPT without inducing VC. 
